Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dermal Defense is a biotechnology company focused on developing advanced topical formulations to protect the skin from chemical and biological threats. Spun out of the University of Pittsburgh, the company's technology creates a functional barrier that not only prevents the penetration of toxins but also actively neutralizes them on the skin's surface. Their primary research is directed toward protecting military personnel and first responders from organophosphate nerve agents and other chemical warfare agents. The company's lead candidates are currently in pre-clinical development, supported by federal research grants from the NIH and Department of Defense. The technology aims to provide a persistent, non-toxic, and easily applied alternative to current decontamination methods.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dermal Defense.